BIOMAT Database Logo BIOMAT Database Logo

Inhibition of rho-kinase by hydroxyfasudil prevents vasopressin-induced myocardial ischemia in Donryu rats by attenuating coronary vasoconstriction. 2005

Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Berlex Biosciences, Richmond, CA 94804, USA.

BACKGROUND Inhibition of rho-kinase has been shown to attenuate vasopressin (AVP)-induced myocardial ischemia measured as S-wave depression in Donryu rats. This has been attributed to a direct inhibitory effect on AVP-induced coronary vasoconstriction. However, since AVP also increased mean arterial blood pressure (MAP) which was attenuated by the rho-kinase inhibitors used, the prevention of myocardial ischemia could have been due to effects on afterload. RESULTS The purpose of this study was to determine if rho-kinase inhibition prevents S-wave depression independent of the effects on blood pressure. In anesthetized Donryu rats (200-340 g), infusion of AVP (0.1 IU/kg) resulted in a sustained increase in MAP (DeltaMAP=46+/-7 mm Hg) and a transient S-wave depression (-90+/-20 microV). Infusion of phenylephrine titrated to achieve a comparable pressor response (DeltaMAP=52+/-2 mm Hg) resulted in a significantly smaller S-wave depression (-30+/-20 microV). Pretreatment with the rho-kinase inhibitor, hydroxyfasudil (3 mg/kg), decreased MAP by -28+/-2 mm Hg and significantly attenuated AVP-induced S-wave depression (-10+/-10 microV) compared to AVP. When rats were pretreated with phenylephrine titrated to maintain MAP, hydroxyfasudil still significantly attenuated AVP-induced S-wave depression (-14+/-12 microV). Hydralazine (1 mg/kg), which lowered MAP by -36+/-5 mm Hg, had no significant effect on AVP-induced S-wave depression (-105+/-32 microV). CONCLUSIONS These data indicate that inhibition of rho-kinase with hydroxyfasudil attenuates AVP-induced myocardial ischemia independent of changes in MAP and are consistent with an inhibitory effect on coronary vasoconstriction.

UI MeSH Term Description Entries
D008297 Male Males
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D004562 Electrocardiography Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY. 12-Lead ECG,12-Lead EKG,12-Lead Electrocardiography,Cardiography,ECG,EKG,Electrocardiogram,Electrocardiograph,12 Lead ECG,12 Lead EKG,12 Lead Electrocardiography,12-Lead ECGs,12-Lead EKGs,12-Lead Electrocardiographies,Cardiographies,ECG, 12-Lead,EKG, 12-Lead,Electrocardiograms,Electrocardiographies, 12-Lead,Electrocardiographs,Electrocardiography, 12-Lead
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D014661 Vasoconstriction The physiological narrowing of BLOOD VESSELS by contraction of the VASCULAR SMOOTH MUSCLE. Vasoconstrictions
D014665 Vasodilator Agents Drugs used to cause dilation of the blood vessels. Vasoactive Antagonists,Vasodilator,Vasodilator Agent,Vasodilator Drug,Vasorelaxant,Vasodilator Drugs,Vasodilators,Vasorelaxants,Agent, Vasodilator,Agents, Vasodilator,Antagonists, Vasoactive,Drug, Vasodilator,Drugs, Vasodilator
D017202 Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION). Heart Disease, Ischemic,Ischemia, Myocardial,Ischemic Heart Disease,Disease, Ischemic Heart,Diseases, Ischemic Heart,Heart Diseases, Ischemic,Ischemias, Myocardial,Ischemic Heart Diseases,Myocardial Ischemias
D017346 Protein Serine-Threonine Kinases A group of enzymes that catalyzes the phosphorylation of serine or threonine residues in proteins, with ATP or other nucleotides as phosphate donors. Protein-Serine-Threonine Kinases,Serine-Threonine Protein Kinase,Serine-Threonine Protein Kinases,Protein-Serine Kinase,Protein-Serine-Threonine Kinase,Protein-Threonine Kinase,Serine Kinase,Serine-Threonine Kinase,Serine-Threonine Kinases,Threonine Kinase,Kinase, Protein-Serine,Kinase, Protein-Serine-Threonine,Kinase, Protein-Threonine,Kinase, Serine-Threonine,Kinases, Protein Serine-Threonine,Kinases, Protein-Serine-Threonine,Kinases, Serine-Threonine,Protein Kinase, Serine-Threonine,Protein Kinases, Serine-Threonine,Protein Serine Kinase,Protein Serine Threonine Kinase,Protein Serine Threonine Kinases,Protein Threonine Kinase,Serine Threonine Kinase,Serine Threonine Kinases,Serine Threonine Protein Kinase,Serine Threonine Protein Kinases
D047908 Intracellular Signaling Peptides and Proteins Proteins and peptides that are involved in SIGNAL TRANSDUCTION within the cell. Included here are peptides and proteins that regulate the activity of TRANSCRIPTION FACTORS and cellular processes in response to signals from CELL SURFACE RECEPTORS. Intracellular signaling peptide and proteins may be part of an enzymatic signaling cascade or act through binding to and modifying the action of other signaling factors. Intracellular Signaling Peptides,Intracellular Signaling Proteins,Peptides, Intracellular Signaling,Proteins, Intracellular Signaling,Signaling Peptides, Intracellular,Signaling Proteins, Intracellular

Related Publications

Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm.
January 2003, Journal of the American College of Cardiology,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Inhibition of Rho kinase by hydroxyfasudil attenuates brain edema after subarachnoid hemorrhage in rats.
February 2012, Neurochemistry international,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Coronary vasoconstriction induced by vasopressin. Production of myocardial ischemia in dogs by constriction of nondiseased small vessels.
June 1991, Circulation,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Effects of Rho-kinase inhibitor on vasopressin-induced chronic myocardial damage in rats.
November 2002, Life sciences,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Rho-Kinase inhibition decreases focal cerebral ischemia-induced glial activation in rats.
January 2022, Journal of central nervous system disease,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Rho-kinase inhibition blunts renal vasoconstriction induced by distinct signaling pathways in vivo.
January 2003, Journal of the American Society of Nephrology : JASN,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
[Role of autophagy in fasudil-induced Rho kinase inhibition for protection against myocardial ischemia-reperfusion injury in rats].
December 2016, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Myocardial ischemia caused by distal coronary vasoconstriction.
December 1992, The American journal of cardiology,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Beneficial effect of hydroxyfasudil, a specific Rho-kinase inhibitor, on ischemia/reperfusion injury in canine coronary microcirculation in vivo.
February 2005, Journal of the American College of Cardiology,
Jon Vincelette, and Rene Pagila, and Kohichi Kawai, and Masaaki Ishii, and Yuko Horimizu, and Ronald Vergona, and Mark E Sullivan, and John Morser, and William P Dole, and Yi-Xin Wang
Transmyocardial revascularization ameliorates ischemia by attenuating paradoxical catecholamine-induced vasoconstriction.
April 2007, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology,
Copied contents to your clipboard!